PolyPid Ltd. Logo

PolyPid Ltd.

Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.

PYPD | US

Overview

Corporate Details

ISIN(s):
IL0011326795
LEI:
Country:
United States of America
Address:
18 HASIVIM STREET, 4959376 PETACH TIKVA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PolyPid Ltd. is a late-stage biopharmaceutical company focused on developing and commercializing locally administered therapies to improve surgical outcomes. The company's proprietary PLEX™ (Polymer-Lipid Encapsulation) technology is a drug delivery platform designed for the localized, controlled, and prolonged release of therapeutic agents. Its lead product candidate, D-PLEX₁₀₀, is in advanced clinical development for the prevention of surgical site infections (SSIs) following abdominal colorectal surgery. PolyPid is also leveraging its PLEX platform to expand its pipeline into other high-value markets, including oncology and metabolic diseases, with a long-acting GLP-1 receptor agonist delivery system for the diabetes and weight loss market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PolyPid Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PolyPid Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PolyPid Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany
SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden
STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea
052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan
4888
StemRIM Inc. Logo
Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.
Japan
4599
STENOCARE A/S Logo
Develops and distributes prescription medical cannabis oils in Northern Europe and Australia.
Denmark
STENO
Stoke Therapeutics, Inc. Logo
Developing RNA-based medicines for genetic diseases by increasing protein from the healthy gene.
United States of America
STOK
ST PHARM CO., LTD. Logo
A global CDMO specializing in APIs and RNA therapeutics for the gene therapy market.
South Korea
237690
Structure Therapeutics Inc. Logo
Develops oral small molecule drugs for chronic conditions like metabolic diseases and obesity.
United States of America
GPCR
Sugentech, Inc. Logo
Develops advanced in-vitro diagnostic systems for hospitals, clinics, and at-home use.
South Korea
253840

Talk to a Data Expert

Have a question? We'll get back to you promptly.